UiPath’s (PATH) Neutral Rating Reiterated at Bank of America

Bank of America reiterated their neutral rating on shares of UiPath (NYSE:PATH – Free Report) in a research report report published on Thursday, Marketbeat reports. Bank of America currently has a $16.00 price objective on the healthcare company’s stock, down from their prior price objective of $30.00. Several other research analysts also recently commented on […]

Leave a Reply

Your email address will not be published.

Previous post TriSalus Life Sciences (NASDAQ:TLSI) Coverage Initiated by Analysts at Canaccord Genuity Group
Next post MongoDB (NASDAQ:MDB) Price Target Cut to $325.00 by Analysts at Canaccord Genuity Group